Karyopharm Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $169.3M | $-79.7M | $190.5M |
| FY2022 | — | $-16.7M | $135.2M |
| FY2023 | — | $-136.2M | $52.2M |
| FY2024 | — | $-186.0M | $62.5M |
| FY2025 | — | $-292.9M | $60.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $169.3M | $-79.7M | $190.5M |
| FY2022 | — | $-16.7M | $135.2M |
| FY2023 | — | $-136.2M | $52.2M |
| FY2024 | — | $-186.0M | $62.5M |
| FY2025 | — | $-292.9M | $60.5M |